Clinical Trial Update: Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia [Phase 2]

View source ↗

Summary

A Phase 2 safety study of carbamylated erythropoietin in patients with Friedreich's ataxia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• Carbamylated Erythropoietin (carbamylated erythropoietin)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Friedreich's Ataxia | Phase 2 | Status: COMPLETED